Short Summary
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
Detailed Summary
Dr. Falk Pharma GmbH (Petitioner) challenged the validity of U.S. Patent 11260061 before the PTAB, asserting obviousness over prior art references including Perrett and Dohil2009 under 35 U.S.C. § 103. The Board found that Petitioner showed a reasonable likelihood of prevailing on Ground 1 (Perrett). A key component of the decision involved claim construction, where the Board defined 'adsorbed onto a pharmaceutically acceptable carrier' as meaning 'adhered to or retained on a surface of a pharmaceutically acceptable carrier.' This finding allowed the Petitioner to advance arguments that the blending process in Perrett implicitly leads to the claimed adsorption limitation.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Dr. Falk Pharma GmbH vs Ellodi Pharmaceuticals LP is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Abbott Laboratories et al.vsMIRACOR MEDICAL SA
Abbott Laboratories has filed an IPR petition seeking cancellation of claims 1‑7, 10, and 12‑13 of Miracor’s U.S. Patent 11,351,356 covering a catheter‑based LVAD. The petition argues that four prior‑art references disclose every claim limitation, making the claims obvious under §103. The Board has not yet ruled on institution or denial.
Tempus AI, Inc.vsGuardant Health Inc.
Guardant Health settled its digital sequencing patent dispute with Foundation Medicine for $25 million plus royalties, granting a non‑exclusive license and dismissing all related litigation.
Google LLCvsSecure Communication Technologies, LLC
Google petitions the PTAB to invalidate a proximity‑marketing patent, arguing that its claims are obvious over prior‑art systems like Perttila, Insolia and Davis. The petition seeks institution of the IPR on claims 19‑23, 25‑26 and 28‑29.
Apple Inc. et al.vsHEADWATER RESEARCH LLC
The PTAB denied Samsung, Google and other petitioners' request for Director Review of the Final Written Decision in IPR2024-00341, leaving the original decision in place.
Harbor Freight Tools USA, Inc. et al.vsChampion Power Equipment, Inc.
Harbor Freight Tools USA and MWE Investments settled their IPR challenges against Champion Power's generator patent, resulting in the Board terminating the proceedings for those parties.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.